ArticleDermatology practical & conceptual2025
Stabilizing Progressive Vitiligo with Systemic Treatment: Identifying Factors Associated With Patients Requiring Prolonged Treatment Duration.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with active vitiligo are treated with systemic immunosuppressants to halt disease progression. However, clinical features associated with patients whose condition is more difficult to control are unknown.
objectiveThis study aimed to identify the clinical features of patients requiring extended periods of systemic immunosuppressants and the real-world clinical course of active vitiligo patients receiving systemic treatments.
methodsThis was a single-center retrospective study. Records of actively progressing vitiligo patients from September 2017 to August 2023 were reviewed.
resultsOne hundred and fifty-nine patients with non-segmental actively progressing vitiligo were enrolled. In the six-month follow-up period, 101 (63.52%) patients required oral systemic immunosuppressants for ≤ 16 weeks without reactivation (Group 1), 51 (32.08%) patients required continuous systemic immunosuppressants for more than 16 weeks to achieve disease stabilization (Group 2), and seven (4.4%) patients achieved disease stabilization ≤16 weeks of oral immunosuppressants but recurred within nine months after stabilization (Group 3). Patients in Group 2 were significantly younger (39.69±11.51 vs. 46.47±14.91 years old; P=0.013) and had a lower proportion of facial involvement (56.86% vs. 76.24%; P=0.016) compared to Group 1. Similarly, both age (odds ratio (OR): 0.968; P=0.016) and facial involvement (OR: 0.432; P=0.023) were identified as significant factors associated with decreased risk for Group 2. At one-year follow-up, 10.89% of Group 1 patients experienced disease reactivation.
conclusionsOlder patients and patients with facial involvement were more likely to achieve disease stabilization. Careful photo documentation is essential to optimal vitiligo management as disease reactivation is common after systemic treatment, even if initial disease stabilization is achieved.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.